Charles C. Guo, M.D.
Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div
About Dr. Charles C. Guo
Dr. Charles Guo is a Professor and Section Chief of Genitourinary (GU) Pathology in the Department of Pathology at the University of Texas MD Anderson Cancer Center. After received his MD from Qingdao University Medical College and MSc from Chinese Academy of Medical Sciences, Dr. Guo moved to the US for postgraduate training in laboratory research. Subsequently he completed his pathology residency training at New York University Medical Center followed by a GU pathology fellowship at Johns Hopkins University School of Medicine. Since his appointment as Assistant Professor at MD Anderson in 2006, he has distinguished himself in both diagnostic pathology and multidisciplinary research related to neoplastic diseases of the GU system. His daily practice is focused on pathologic diagnosis of GU neoplastic diseases, including prostate, urinary bladder, kidney, and testicular cancers. He evaluates a large number of biopsies and surgical specimens from patients who are treated at MD Anderson. He also reviews a variety of complex GU cases from patients who come to MD Anderson for treatment with their pathology materials from all over the world. In addition, he frequently provides expert opinions on challenging GU consultation cases. Over the years, he has gained extensive knowledge and experience as well as developed leading-edge skills in GU pathology services, while working closely with his clinical colleagues to help optimizing treatment plans and predicting clinical outcomes in personalized medicine. He has published over 200 manuscripts and book chapters related to GU pathology, and he has been invited to give lectures at national and international meetings.
Present Title & Affiliation
Primary Appointment
Section Chief, Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Pathology, Anatomical, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Pathology, Anatomical, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
1. To analyze important molecular signals and alterations in development and progression of prostate cancer (protein kinase CK2, MAPK, telomerase and TMPRSS2-ERG gene fusion).
2. To investigate genomic expression and molecular subtyping of bladder urothelial carcinoma histologic variants.
3. To study clinicopathologic features of somatic transformation in testicular germ cell tumors.
Clinical Interests
- Prostate cancer
- Bladder cancer
- Kidney cancer
- Testicular cancer
- Penile cancer
- Adrenal cancer
- Intraoperative frozen section
- Autopsy
Education & Training
Degree-Granting Education
| 1993 | Chinese Academy of Medical Sciences, Beijing, CN, Endocrinology and Molecular Biology, M.Sc |
| 1990 | Qingdao University Medical College, Qingdao, CN, Medicine, MD |
Postgraduate Training
| 2005-2006 | Clinical Fellowship, Genitourinary Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland |
| 2001-2005 | Medical Residency, Anatomic and Clinical Pathology, New York University Medical Center, New York, New York |
| 1998-2001 | Research Associate, Surgery and Cancer Biology, Duke University Medical Center, Durham, North Carolina |
| 1995-1998 | Research Associate, Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota |
| 1995-1995 | Research Fellowship, Neuroscience, Oregon National Primate Research Center, Beaverton, Oregon |
| 1994-1994 | Research Fellowship, Pharmacology and Neuroscience, University of Iowa College of Medicine, Iowa City, Iowa |
| 1993-1994 | Research Fellowship, Physiology, Chinese Academy of Medical Sciences, Beijing |
Licenses & Certifications
| 2007 | Texas State Medical License |
| 2005 | American Board of Pathology (Anatomic and Clinical Pathology) |
| 2004 | New York State Medical License |
Experience & Service
Faculty Academic Appointments
Associate Professor, Pathology, Anatomical, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Assistant Professor, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012
Administrative Appointments/Responsibilities
Chief, Genitourinary Pathology Section, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Extramural Institutional Committee Activities
Member, Search Committee of the Chair of Urology Department, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Institutional Research Grants Applications Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2015 - 2018
Member, Ad Hoc Committee of Searching the Director of Research Operations in Department of Pathology, The University of Texas MD Anderson Cancer Center, 2011
Member, Ad Hoc Committee of Searching the Director of Clinical Operations in Department of Pathology, The University of Texas MD Anderson Cancer Center, 2010
Associate Member, The Institutional Review Board 1, The University of Texas MD Anderson Cancer Center, 2009 - 2010
Abstract Reviewer, Trainee Research Day 2009 Event, The University of Texas MD Anderson Cancer Center, 2009
Member, Institutional Research Grants Program Study Section Committee for Clinical, Translational, and Population-Based Research Projects, The University of Texas MD Anderson Cancer Center, 2009 - 2017
Editorial Activities
Member of the Editorial Board, Human Pathology, 2025 - Present
Guest Editor, Journal of Clinical and Translational Pathology, 2022 - 2023
Associate Editor, Journal of Clinical and Translational Pathology, 2021 - Present
Member of Editorial Review Board, BioMed Research International, 2014 - 2017
Member of Editorial Review Board, USCAP Abstract Review Board, 2008 - 2011
Honors & Awards
| 1999 - 2000 | Armstrong Cancer Biology Award, Duke Comprehensive Cancer Center |
| 1990 - 1993 | Academic Scholarship, Chinese Academy of Medical Sciences |
| 1985 - 1990 | Academic Achievements, First Place, Qingdao Medical College |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Diagnosis of Renal Cell Carcinoma: A Contempora and Molecular Approach & Challenging Diagnostic Issues of Prostatic Cancer on Molecular Subtypes. Invited. The William O. Russell Annual Conference: The Nuts and Bolts in Surgical Pathology. Houston, Texas, US.
- 2026. Recent Developments in the Pathology of Testicular Germ Cell Tumors. Invited. Baylor Pathology Citywide Grand Rounds. Houston, Texas, US.
- 2025. Rapid Evolution of Biomarkers and Therapies in Bladder Cancer. Invited. Cancer Biomarkers Conference VII. Houston, Texas, US.
- 2025. The Multiverse of Mechanistic Processes Impacting Immunity. Invited. James P. Allison Institute Third Scientific Symposium. Houston, Texas, US.
- 2019. Badder cancer histologic variants. Conference. Badder cancer histologic variants. Houston, TX, US.
- 2019. Clinically aggressive bladder cancer variants - Pathology and Genomics. Conference. Clinically aggressive bladder cancer variants - Pathology and Genomics. Houston, TX, US.
- 2009. Chromosomal translocations: A journey from rare to common human malignancies. Conference. Chromosomal translocations: A journey from rare to common human malignancies. Houston, TX, US.
- 2006. Telomerase: a potential therapeutic target in prostate cancer. Conference. Telomerase: a potential therapeutic target in prostate cancer. Houston, TX, US.
Regional Presentations
- 2026. Molecular Profile of Upper Tract Urothelial Carcinoma: An Analysis of 110 Cases by Next-Generation Sequencing. Invited. The United States and Canadian Academy of Pathology. San Antonio, Texas, US.
- 2026. Deficiency of Methylthioadenosine Phosphorylase is Associated with Poor Clinical Outcome in Upper Urinary Tract Urothelial Carcinoma. Invited. The United States and Canadian Academy of Pathology. San Antonio, Texas, US.
- 2026. Clinicopathologic and Molecular Study of 15 Cases of Urothelial Carcinoma with Gene Fusions. Invited. The United States and Canadian Academy of Pathology. San Antonio, Texas, US.
- 2026. FOXA1 is a Highly Sensitive Diagnostic Marker for Prostate Cancer Including Small Cell Carcinoma of Prostate. Invited. The United States and Canadian Academy of Pathology. San Antonio, Texas, US.
- 2025. Prostate cancer vs. bladder cancer - A common diagnostic pitfall in pathology. Invited. The 10th Annual Conference of the Alliance of North American Chinese Physicians. Dallas, TX, US.
- 2025. Recent development in Bladder Cancer: Pathology and Genomics. Invited. Department of Pathology Lecture Series. Galveston, TX, US.
- 2025. Genitourinary Pathology Slides Seminar. Invited. Department of Pathology Lecture Series. Galveston, TX, US.
National Presentations
- 2026. Dive deep with the most brilliant minds in Oncology and Cancer Leadership to get a glimpse of the discussions happening at cancer centers and healthsystems across the country, and leave with clear action items to improve your organization. Invited. Becker's Oncology Executive Summit. Chicago, Illinois, US.
- 2025. Recent development in bladder cancer histologic subtypes. Invited. The 11th Annual Diagnostic Course. Orlando, FL, US.
- 2024. Invasive Urothelial Carcinoma - Histologic Subtype and Molecular Classification. Conference. Invasive Urothelial Carcinoma - Histologic Subtype and Molecular Classification. Online, Zhejiang, US.
- 2023. Variant Histology for Urothelial Carcinoma. Conference. Variant Histology for Urothelial Carcinoma. Online, US.
- 2023. Pathology or 'Markers': What is more important?. Conference. Pathology or 'Markers': What is more important?. Chicago, IL, US.
- 2023. Somatic-Type Malignancy in Germ Cell Tumor. Conference. Somatic-Type Malignancy in Germ Cell Tumor. New Oleans, LA, US.
- 2022. Immunohistochemistry and Molecular studies in Genitourinary Cancers. Conference. Immunohistochemistry and Molecular studies in Genitourinary Cancers. Online, US.
- 2021. New Entity and Histologic Variants of Prostate Cancer. Conference. New Entity and Histologic Variants of Prostate Cancer. Online, US.
- 2020. Recent Development in Pathologic Diagnosis of Prostate Cancer. Conference. Recent Development in Pathologic Diagnosis of Prostate Cancer. Online, US.
- 2020. Somatic-Type Malignancy in Testicular Germ Cell Tumor –A Clinicopathologic Analysis of 53 Cases. Conference. Somatic-Type Malignancy in Testicular Germ Cell Tumor –A Clinicopathologic Analysis of 53 Cases. Los Angeles, CA, US.
- 2020. Genomic characterization of bladder small cell carcinoma. Conference. Genomic characterization of bladder small cell carcinoma. Los Angeles, CA, US.
- 2019. Clinically Aggressive Bladder Cancer Histologic Variants. Conference. Clinically Aggressive Bladder Cancer Histologic Variants. Los Angeles, CA, US.
- 2019. Clinicopathologic Analysis of Bladder Cancer Involving Muscularis Mucosae or Smooth Muscle of an Indeterminate Type on Transurethral Resection Specimens. Conference. Clinicopathologic Analysis of Bladder Cancer Involving Muscularis Mucosae or Smooth Muscle of an Indeterminate Type on Transurethral Resection Specimens. National Harbor, MD, US.
- 2019. Genome-Wide Characterization of Sarcomatoid Bladder Cancer. Conference. Genome-Wide Characterization of Sarcomatoid Bladder Cancer. National Harbor, MD, US.
- 2017. Small Cell Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of 81 Cases. Conference. Small Cell Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of 81 Cases. San Antonio, TX, US.
- 2016. Molecular Characterization of Clinically Aggressive Micropapillary Bladder Cancer. Conference. Molecular Characterization of Clinically Aggressive Micropapillary Bladder Cancer. Seattle, WA, US.
- 2015. Recent advances in diagnosis of testicular germ cell tumors. Conference. Recent advances in diagnosis of testicular germ cell tumors. Flushing, NY, US.
- 2015. Gene expression profile of bladder micropapillary urothelial carcinoma. Conference. Gene expression profile of bladder micropapillary urothelial carcinoma. Boston, MA, US.
- 2013. Recent Advances in Diagnosis of Prostate Cancer: A Combined Histologic and Molecular Approach. Conference. Pathology of the 21st Century. Guangzhou, Guangdong, US.
- 2012. Genitourinary Pathology Case Presentation. Conference. Pathology of 21st Century. Houston, TX, US.
- 2010. Pathology for Urologists. Conference. Annual Board Review Course. Addison, TX, US.
- 2009. Recent advances in genitourinary pathology. Conference. 4th Investigational Pathology Symposium: A Scientific Meeting of CAPA. Boston, MA, US.
- 2008. Small cell carcinoma of the prostate with TMPRSS2-ERG gene fusion. Conference. Pathology of 21st Century. Houston, TX, US.
- 2008. Primary Mediastinal Germ Cell Tumors with Somatic Transformation to Angiosarcoma: A Report of 9 Cases. Conference. Primary Mediastinal Germ Cell Tumors with Somatic Transformation to Angiosarcoma: A Report of 9 Cases. Denver, CO, US.
- 2008. Somatic Transformation to Sarcoma in Testicular Germ Cell Tumors: A Clinicopathologic Analysis of 33 Cases. Conference. Somatic Transformation to Sarcoma in Testicular Germ Cell Tumors: A Clinicopathologic Analysis of 33 Cases. Denver, CO, US.
- 2007. Prognostic significance of positive surgical margins in radical prostatectomies: An analysis based on their anatomic locations. Conference. Prognostic significance of positive surgical margins in radical prostatectomies: An analysis based on their anatomic locations. San Diego, CA, US.
- 2006. Prognostic significance of non-invasive squamous lesions in urinary bladder. Conference. Prognostic significance of non-invasive squamous lesions in urinary bladder. Atlanta, GA, US.
- 2006. Intraductal carcinoma of the prostate: Histologic features and clinical significance. Conference. Intraductal carcinoma of the prostate: Histologic features and clinical significance. Atlanta, GA, US.
International Presentations
- 2026. Biomarkers in bladder cancer - HER2 and Other/Emerging Drug Antibody Conjugates. Invited. Multidisciplinary Expert Consultation Conference on Precision Biomarker Testing in Bladder and Prostate Cancer. Stockholm, SE.
- 2026. Pathology and Translational Priorities in Transurethral Resection of Bladder Tumors. Invited. International Bladder Cancer Group 2026 Annual Retreat. Houston, US.
- 2026. Innovations in Pathology: Driving Precision Medicine and Global Health. Invited. 24th European Pathology Conference. Paris, FR.
- 2024. Assessment of Basal and Luminal Molecular Subtypes in Bladder Cancer. Conference. Assessment of Basal and Luminal Molecular Subtypes in Bladder Cancer. Budapest, HU.
- 2023. Specimen Handling, Staging, and Reporting of Prognostic Parameters for Urachal Neoplasms. Conference. Specimen Handling, Staging, and Reporting of Prognostic Parameters for Urachal Neoplasms. Dublin, IE.
- 2022. Updates on prostate cancer from the 2022 World Health Organizaiton Classification. Conference. Updates on prostate cancer from the 2022 World Health Organizaiton Classification. Online, US.
- 2019. Immunohistochemistry Aids Molecular Classification of Bladder Cancer by Genomic Analysis. Conference. Immunohistochemistry Aids Molecular Classification of Bladder Cancer by Genomic Analysis. Singapore, SG.
- 2019. Genomic and Immunohistochemical Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Conference. Genomic and Immunohistochemical Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Aarhus, DK.
- 2018. Use of Immunohistochemistry in Molecular Classification of Bladder Cancer. Conference. International Bladder Cancer Network. Rotterdam, NL.
- 2018. Genomic profile of sarcomatoid carcinoma of the bladder. Conference. Genomic profile of sarcomatoid carcinoma of the bladder. Rotterdam, NL.
- 2018. Recent development in bladder cancer. Conference. Recent development in bladder cancer. Beijing, CN.
- 2018. Progression to Sarcomatoid Bladder Cancer is Associated with Dysregulation of Chromatin Remodeling and Cell Cycle Circuits. Conference. Progression to Sarcomatoid Bladder Cancer is Associated with Dysregulation of Chromatin Remodeling and Cell Cycle Circuits. Vancouver, CA.
- 2017. Genomic Profile of Sarcomatoid Bladder Cancer. Conference. Genomic Profile of Sarcomatoid Bladder Cancer. Lisbon, PT.
- 2016. Distinct genomic expression profile in micropapillary bladder cancer. Conference. Distinct genomic expression profile in micropapillary bladder cancer. Bochum, DE.
- 2015. Recent advances in immunohistochemistry and genomics of bladder urothelial carcinoma. Conference. Recent advances in immunohistochemistry and genomics of bladder urothelial carcinoma. Beijing, CN.
- 2014. Pathologic and clinical features of familial renal cell carcinoma. Conference. Pathologic and clinical features of familial renal cell carcinoma. Chongqing, CN.
- 2014. Testicular germ cell tumor with somatic transformation. Conference. Testicular germ cell tumor with somatic transformation. Chongqing, CN.
- 2014. New advance in prostate pathology and its impact on clinical practice. Conference. the 4th Renji Multidisciplinary Meeting on Urological Cancers. Shanghai, CN.
- 2014. New immunohistochemical markers for bladder urothelial carcinoma variants. Conference. New immunohistochemical markers for bladder urothelial carcinoma variants. Vancouver, CA.
- 2013. Urothelial Carcinomas: Multi‐Modal Management of Difficult Cases in NMIBC. Conference. ASCO GU Symposium. Orlando, US.
- 2012. Updates of prostate cancer. Conference. Updates of prostate cancer. Wuhan, CN.
- 2012. High-grade prostatic intraepithelial neoplasia is a precursor of prostate cancer: histologic and molecular evidences. Conference. High-grade prostatic intraepithelial neoplasia is a precursor of prostate cancer: histologic and molecular evidences. Wuhan, CN.
- 2012. Recent development in genitourinary pathology. Conference. Recent development in genitourinary pathology. Vancouver, CA.
- 2011. How to use immunohistochemistry in the diagnosis of testicular germ cell tumors. Conference. How to use immunohistochemistry in the diagnosis of testicular germ cell tumors. Zibo, CN.
- 2011. The TMPRSS2-ERG gene fusion is a valuable marker in pathologic evaluation of prostate cancer. Conference. The TMPRSS2-ERG gene fusion is a valuable marker in pathologic evaluation of prostate cancer. Shanghai, CN.
- 2011. The value of immunohistochemistry in the diagnosis of testicular germ cell tumors. Conference. The value of immunohistochemistry in the diagnosis of testicular germ cell tumors. Shanghai, CN.
Formal Peers
- 2025. Genitourinary Pathology Slides Seminar. New Haven, CT, US.
- 2025. Molecular Classification of Bladder Urothelial Carcinoma and Histologic Subtypes. New Haven, CT, US.
- 2023. Recent Advances in The Pathology and Genomics of Bladder Cancer. Invited. Los Angeles, CA, US.
- 2022. New Developments in the Pathology of Testicular Cancer. Invited. Durham, NC, US.
- 2019. Recent Advances in Bladder Cancer Histologic Variants. Invited. Taipei, TW.
- 2019. Clinically Aggressive Bladder Cancer Histologic Variants - Pathology and Genomics. Invited. Seoul.
- 2019. Recent Developments in WHO Classification of Prostate Cancer. Invited. Guangzhou, Guangdong, CN.
- 2019. Bladder Cancer Aggressive Clinical Variants - Pathology and Genomics. Invited. Bethesda, MD, US.
- 2017. Bladder urothelial carcinoma variants - pathology and genomics. Invited. Shanghai, CN.
- 2017. Recent development in Bladder Urothelial Carcinoma and Histologic Variants: Pathology and Genomics. Invited. Los Angeles, CA, US.
- 2016. Histologic classification of bladder cancer in tissue bank. Invited. Denver, CO, US.
- 2016. How to interpret bladder biopsy specimens. Invited. Houston, TX, US.
- 2015. Invasive Urothelial Carcinoma of the Urinary Bladder and Variants: Pathologic and Genomic Analysis. Invited. Los Angeles, CA, US.
- 2014. How to diagnose familial renal cell carcinoma. Invited. Chengdu, Sichuan, CN.
- 2014. Pathologic features of prostate cancer on biopsy specimens. Invited. Nanjing, Jiangsu, CN.
- 2013. Difficult genitourinary pathology cases review. Invited. Beijing, CN.
- 2013. New developments in the diagnosis of prostate cancer. Invited. Beijing, CN.
- 2012. Recent advances in prostate pathology. Invited. Xi'an, Shaanxi, CN.
- 2012. Review of challenging genitourinary pathology cases. Invited. Xi'an, Shaanxi, CN.
- 2011. Challenging genitourinary oncologic cases. Invited. New York, NY, US.
- 2011. The value of TMPRSS2-ERG gene fusion in pathologic evaluation of prostate cancer. Invited. New York, NY, US.
- 2011. Using the TMPRSS2-ERG gene fusion in pathologic analysis of prostate cancer. Invited. Cleveland, OH, US.
- 2011. Interesting genitourinary pathology cases. Invited. Cleveland, OH, US.
- 2011. Using the TMPRSS2-ERG gene fusion in pathologic evaluation of prostate cancer. Invited. Shanghai, CN.
- 2011. How to diagnose testicular germ cell tumors. Invited. Montreal, Quebec, CA.
- 2011. The TMPRSS2-ERG gene fusion is a useful marker in pathologic evaluation of prostate cancer. Invited. Montreal, Quebec, CA.
- 2011. The Value of the TMPRSS2-ERG gene fusion in the pathologic evaluation of prostate cancer. Invited. Montreal, Quebec, CA.
- 2011. Testicular germ cell tumors. Invited. Los Angeles, CA, US.
- 2006. Regulation of telomerase by androgen in prostate cancer. Invited. Chicago, IL, US.
- 2006. Inhibition of telomerase is related to the lifespan and tumorigenicity of human prostate cancer cells. Invited. Washington, DC, US.
- 2006. Role of telomerase in prostate cancer. Invited. Buffalo, NY, US.
- 2005. Telomerase: A potential therapeutic target in prostate cancer. Invited. New York, NY, US.
- 2005. Urothelial Neoplasms in Biopsy of the Bladder. Invited. Stony Brook, NY, US.
- 2005. Telomerase: A potential therapeutic target in prostate cancer. Invited. New York, NY, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Targeting PRMT5-BRD4 Axis to Enhance FGFR3 Inhibitor Efficacy in FGFR3-Altered Bladder Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00028966 |
| Date: | 2026 - 2031 |
| Title: | Advancing Front-Line Therapy for MTAP-Loss Bladder Cancer by Targeting DNMT1-Mediated Suppression of Viral Mimicry Response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA254988-06 |
| Date: | 2024 - 2029 |
| Title: | Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy - Pathology Core |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 1P01CA296429-01 |
| Date: | 2022 - Present |
| Title: | Monitoring of Field Effects for the Detection of Bladder Cancer |
| Funding Source: | CPRIT |
| Role: | Collaborator |
| ID: | RP220021 |
| Date: | 2021 - 2026 |
| Title: | Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA254988-01A1 |
| Date: | 2018 - 2021 |
| Title: | A biomarker-based, combination therapy with immune checkpoint blockade and pemetrexed for MTAP-deficient metastatic bladder cancer |
| Funding Source: | Doris Duke Charitable Foundation |
| Role: | Collaborator |
| Date: | 2018 - 2021 |
| Title: | Study of combination therapy with immune checkpoint blockade and chemotherapy for MTAP-deficient metastatic bladder cancer |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | Collaborator |
| Date: | 2018 - 2021 |
| Title: | Targeting MTAP-deficient metastatic urothelial bladder cancer with pemetrexed and immune checkpoint therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | FP00002591 |
| Date: | 2017 - 2021 |
| Title: | Effect of pemetrexed on MTAP-deficient metastatic urothelial bladder cancer |
| Funding Source: | Khalifa Physician Scientist Award |
| Role: | Collaborator |
| Date: | 2017 - 2019 |
| Title: | Genomic Characterization of Metachronous Upper Tract and Bladder Urothelial Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | FP00000452 |
| Date: | 2017 - 2017 |
| Title: | Genomic Alterations of Renal Pelvis, Ureter, and Bladder Carcinomas |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | Collaborator |
| ID: | FP00000205 |
| Date: | 2016 - 2021 |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE – Biospecimen and Pathology Core 2 |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | CA140388-06 |
| Date: | 2016 - 2019 |
| Title: | The UT MD Anderson SPORE in Genitourinary Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | CA091846-15S1 |
| Date: | 2016 - 2017 |
| Title: | Molecular Subtype of Bladder Small Cell Carcinoma Based on the Whole Genome Gene Expression Analysis |
| Funding Source: | MDACC Department of Pathology |
| Role: | Co-PI |
| ID: | Mentored trainee award |
| Date: | 2013 - 2014 |
| Title: | Differential miRNA expression in conventional and micropapillary variant urothelial carcinomas of the urinary bladder |
| Funding Source: | MDACC Department of Pathology |
| Role: | Co-PI |
| ID: | Fellows Research Project |
| Date: | 2012 - 2013 |
| Title: | Using Cancer Stem Cell Markers to Predict Cancer Recurrence and Progression in Papillary Urothelial Carcinoma of the Urinary Bladder |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2011 - 2014 |
| Title: | The Cancer Genome Atlas for Bladder Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | HHSN2612010000211 |
| Date: | 2010 - 2011 |
| Title: | The association of small cell carcinoma with cancer stem cells in the urinary bladder |
| Funding Source: | MDACC Department of Pathology |
| Role: | Mentor |
| ID: | N/A |
| Date: | 2008 - 2010 |
| Title: | Relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancer |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2007 - 2011 |
| Title: | Sunitinib, hormonal ablation & external beam radiation therapy for high-risk & locally advanced prostate cancer |
| Funding Source: | Pfizer |
| Role: | Co-I |
| Date: | 2006 - 2009 |
| Title: | TMPRSS2-ERG gene fusion in prostate cancer |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Ibrahim, E, Perez, A, Hegazy, S, Kostyuk, A, Guo, CC. Adenomatoid tumor of the adrenal Gland. Human Pathology Reports 44, 2026. e-Pub 2026.
- South, N, Mihai, IM, Wang, V, Agoumi, M, Guo, CC, Wang, G. Urachal Signet Ring Cell Carcinoma. Current Oncology 33(3), 2026. e-Pub 2026. PMID: 41892181.
- Wang, Y, Zang, C, Li, Z, Guo, CC, Lai, D, Wei, P. A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics. PLoS computational biology 22(2):1-19, 2026. e-Pub 2026. PMID: 41671295.
- Zheng, L, Hu, S, Czerniak, BA, Guo, CC. Two Different Somatic-type Malignancies Arising from a Mediastinal Germ Cell Tumor. Journal of Clinical and Translational Pathology 6(1):32-36, 2026. e-Pub 2026.
- Zang, C, Guo, CC, Wang, Y, Wei, P, Li, Z. TUSCAN. PLoS computational biology 22(3):1-18, 2026. e-Pub 2026. PMID: 41843898.
- Mi, W, Zang, C, Zhao, J, Kamat, A, Wei, P, Hansel, DE, Czerniak, BA, Guo, CC. Mixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma. Human Pathology 163, 2025. e-Pub 2025. PMID: 40780614.
- Downes MR, Lopez-Beltran A, Contieri R, Hansel DE, Paner GP, Shen S, van Rhijn BWG, Al-Ahmadie H, Amin MB, Brunelli M, Comperat E, Cookson MS, Faltas BM, Guo CC, Hartmann A, Kamat AM, Mertens LS, Ross JS, van der Kwast TH, Warrick J, Kristiansen G, Cheng L, Raspollini MR. International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder. Am J Surg Pathol 49(12):e46-e57, 2025. e-Pub 2025. PMID: 40590266.
- Reis H, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, Maclean F, Tsuzuki T, Werneck da Cunha I, Amin MB, Aning J, Aron M, Athanazio D, Bambury RM, Cheng L, Gopalan A, Gulmann C, Guo CC, Harris C, Iyer G, Jimenez RE, Jinzaki M, Kikuchi E, Lal P, Miyai K, Netto GJ, Pan CC, Panebianco V, van Rhijn BW, Siefker-Radtke A, Smith SC, Szarvas T, Wobker SE, Kristiansen G, Paner GP. The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms. Am J Surg Pathol, 2025. e-Pub 2025. PMID: 40471793.
- Acosta, A, Saad, M, Chaux, A, Gordetsky, JB, Zheng, L, Guo, CC, Bikhet, M, Osunkoya, AO, Collins, K, Idrees, MT, Van Leenders, GJ, Gonzalez-Peramato, P, Cornejo, KM, Hirsch, M, Kao, CS, Matoso, A, Magi-Galluzzi, C, Rais-Bahrami, S. Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy. Urology 200:127-134, 2025. e-Pub 2025. PMID: 40250715.
- Shen Y, Zheng L, Zhao J, Wang Y, Chen H, Roy-Chowdhuri S, Kamat AM, Alhalabi O, Gao J, Siefker-Radtke A, Wei P, Hansel DE, Czerniak B, Guo CC. Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing. Hum Pathol 159:105812, 2025. e-Pub 2025. PMID: 40403852.
- Jackson JC, Sanchez D, Joon AY, Estecio MR, Johns AC, Shah AY, Campbell M, Ward JF, Pisters LL, Guo CC, Zhang M, Zacharias NM, Tu SM. Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers. Cells 14(9), 2025. e-Pub 2025. PMID: 40358182.
- Zheng L, Tabet G, Guo CC, Rizvi YO, Raso MG, Liu J, Ding Q, Baraban E, Zhao J. Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Hum Pathol 157:105767, 2025. e-Pub 2025. PMID: 40189026.
- Wang Y, Zang C, Li Z, Guo CC, Lai D, Wei P. A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics. bioRxiv, 2025. e-Pub 2025. PMID: 40027680.
- Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med 14(2):e70594, 2025. e-Pub 2025. PMID: 39831734.
- Myers AA, Fang AM, Moussa MJ, Hwang H, Wilson NR, Campbell MT, Msaouel P, Lee BH, Guo CC, Zhang M, Zhao J, Siefker-Radtke AO, Kamat AM, Alhalabi O. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open 9(11):103964, 2024. e-Pub 2024. PMID: 39471563.
- Tabet GC, Zheng L, Hosseini H, Ward J, Pisters L, Campbell MT, Tu SM, Czerniak B, Guo CC. Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases. Hum Pathol 153:105673, 2024. e-Pub 2024. PMID: 39461379.
- Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun 4(9):2444-2453, 2024. e-Pub 2024. PMID: 39207194.
- Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med 13(12), 2024. e-Pub 2024. PMID: 38929965.
- Zhao J, Shen Y, Guo M, Matin SF, Hansel DE, Guo CC. Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. Am J Clin Pathol 162(5):492-499, 2024. e-Pub 2024. PMID: 38860463.
- Contieri, R, Tan, WS, Grajales, V, Hensley, PJ, Martini, A, Bree, KK, Myers, AA, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Guo, CC, Kamat, A. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
- Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat AM, Alhalabi O, Gao J, Siefker-Radtke A, Hansel DE, Czerniak B, Guo CC. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol 148:1-6, 2024. e-Pub 2024. PMID: 38679207.
- Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin. BJU Int 133(1):63-70, 2024. e-Pub 2023. PMID: 37442564.
- Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol, 2023. e-Pub 2023. PMID: 37922370.
- Riddle N, Parkash V, Guo CC, Shen SS, Perincheri S, Ramirez AS, Auerbach A, Belchis D, Humphrey P. Recent Advances in Genitourinary Tumors Updates From the 5th Edition of the World Health Organization Blue Book Series. Arch Pathol Lab Med , 2023. e-Pub 2023.
- Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. e-Pub 2023. PMID: 37833193.
- Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
- Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
- Baraban E, Ding, CC, White, M, Vohra, P, Simko J, Boyle K, Guo C Zhang M, Dobs A, Ketheeswaran S, Liang F, Epstein JI. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy. American Journal of Surgical Pathology 46(12):1650-1658, 2022. e-Pub 2022.
- Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int 130(5):604-610, 2022. e-Pub 2022. PMID: 34773684.
- Labbate, CV, Hensley, PJ, Miest, T, Qiao, W, Adibi, M, Shah, AY, Chery, LJ, Papadopoulos, JN, Siefker-Radtke, AO, Gao, J, Guo, CC, Czerniak, BA, Navai, N, Kamat, A, Dinney, CP, Campbell, M, Matin, S. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Kinskey, JC, Schwartz, MR, Guo, CC, Ro, JY. Perivascular epithelioid cell tumor in the mediastinum. Human Pathology Reports 29, 2022. e-Pub 2022.
- Guo CC, Czerniak B. Somatic-Type Malignancies in Testicular Germ Cell Tumors. Hum Pathol 127:123-135, 2022. e-Pub 2022. PMID: 35803413.
- Zaleski, M, Chen, H, Roy Chowdhuri, S, Patel, KP, Luthra, R, Routbort, MJ, Kamat, A, Gao, J, Siefker-Radtke, AO, Czerniak, BA, Guo, CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma an analysis of 30 cases by next-generation Sequencing. American journal of clinical pathology 158(2):263-269, 2022. e-Pub 2022. PMID: 35467000.
- Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. Reply by Authors. J Urol 208(2):290-291, 2022. e-Pub 2022. PMID: 35770497.
- Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA. The origin of bladder cancer from mucosal field effects. iScience 25(7), 2022. e-Pub 2022. PMID: 35747385.
- Adibi, M, McCormick, B, Economides, MP, Petros, FG, Xiao, L, Guo, CC, Shah, AY, Kamat, A, Dinney, CP, Navai, N, Gao, J, Siefker-Radtke, AO, Matin, S, Campbell, M. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Moore, JA, Tidwell, R, Lehner, MJ, Campbell, M, Shah, AY, Zhang, M, Guo, CC, Ward, JF, Karam, JA, Wood, CG, Pisters, LL, Tu, S. Very Late Recurrence in Germ Cell Tumor of the Testis. Cancers 14(5), 2022. e-Pub 2022. PMID: 35267435.
- Tu, S, Guo, CC, Chow, DS, Millward, NZ. Stem Cell Theory of Cancer. Cancers 14(6), 2022. e-Pub 2022. PMID: 35326699.
- Guo, CC, Duan, H, Fu, W, He, H, Xie, F, Yang, Z, Zheng, M, Zhang, L. A DNA damage response mutation-related prognostic gene signature associated with survival outcomes and the immune microenvironment in patients with hepatocellular carcinoma. Journal of biological regulators and homeostatic agents 36(1):45-56, 2022. e-Pub 2022.
- Hwang MJ, Hamza A, Zhang M, Tu SM, Pisters LL, Czerniak B, Guo CC. Somatic-Type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol 46(1):11-17, 2022. e-Pub 2022. PMID: 34334690.
- Han, G, Yang, G, Hao, D, Lu, Y, Thein, KZ, Simpson, BS, Chen, J, Sun, R, Alhalabi, O, Wang, R, Dang, M, Dai, E, Zhang, S, Nie, F, Zhao, S, Guo, CC, Hamza, A, Czerniak, BA, Cheng, C, Siefker-Radtke, AO, Bhat, KP, Futreal, A, Peng, G, Wargo, J, Peng, W, Kadara, HN, Ajani, JA, Swanton, C, Litchfield, K, Rodon Ahnert, J, Gao, J, Wang, L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34556668.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Reply by Authors. The Journal of Urology 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Progression of Disease after Bacillus Calmette-Guérin Therapy. Journal of Urology 206(5):1258-1266, 2021. e-Pub 2021. PMID: 34184926.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol S2588-9311(21):00188-7, 2021. e-Pub 2021.
- Wang, G, Yuan, R, Zhou, C, Guo, CC, Villamil, C, Hayes, M, Eigl, B, Black, P. Urinary Large Cell Neuroendocrine Carcinoma. American Journal of Surgical Pathology 45(10):1399-1408, 2021. e-Pub 2021. PMID: 34074810.
- Petros, FG, Choi, W, Qi, Y, Moss, T, Li, R, Su, X, Guo, CC, Czerniak, BA, Dinney, CP, McConkey, DJ, Matin, S. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology 206(3):548-557, 2021. e-Pub 2021. PMID: 33881933.
- Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat SF, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol 28(4):196-208, 2021. e-Pub 2021. PMID: 34128484.
- Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat S, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol 28(4):179-195, 2021. e-Pub 2021. PMID: 34128483.
- Fine, S, Trpkov, K, Amin, MB, Algaba, F, Aron, M, Baydar, D, Lopez-Beltran, A, Brimo, F, Cheville, JC, Colecchia, M, Comperat, EM, Costello, T, Cunha, IW, Delprado, W, DeMarzo, AM, Giannico, G, Gordetsky, JB, Guo, CC, Hansel, DE, Hirsch, M, Huang, J, Humphrey, PA, Jimenez, R, Khani, F, Kong, MX, Kryvenko, ON, Kunju, LP, Lal, P, Latour, M, Lotan, TL, Maclean, F, Magi-Galluzzi, C, Mehra, R, Menon, S, Miyamoto, H, Montironi, R, Netto, G, Nguyen, JK, Osunkoya, AO, Parwani, AV, Pavlovich, CP, Robinson, B, Rubin, MA, Shah, RB, So, JS, Takahashi, H, Tavora, F, Tretiakova, M, True, LD, Wobker, SE, Yang, XJ, Zhou, M, Zynger, DL, Epstein, J. Practice patterns related to prostate cancer grading. Urologic Oncology: Seminars and Original Investigations 39(5):295.e1-295.e8, 2021. e-Pub 2021. PMID: 32948433.
- Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med 145(4):461-493, 2021. e-Pub 2021. PMID: 32589068.
Review Articles
- Shah, RB, Varma, M, Zhou, M, Paner, GP, Amin, MB, Berney, D, Cheng, L, Deng, FM, Downes, MR, Eggener, SE, Ehdaie, B, Epstein, J, Evans, A, Fine, S, Greenland, N, Guo, CC, Han, B, Hirsch, M, Izkowski, KA, Kench, J, Lotan, TL, Magi-Galluzzi, C, Miyamoto, H, Nguyen, JK, Tsuzuki, T, Van Der Kwast, T, Van Leenders, GJ, Williamson, SR, Wobker, SE, Wu, CL, Yang, XJ, Kristiansen, G. The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate. Histopathology 88(1):8-23, 2026. e-Pub 2026. PMID: 41384645.
- Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernandez MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Bladder-sparing Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol 86(6):516-527, 2024. e-Pub 2024. PMID: 39183090.
- Riddle, ND, Parkash, V, Guo, CC, Shen, SS, Perincheri, S, Ramirez, AS, Auerbach, A, Belchis, D, Humphrey, PA. Recent Advances in Genitourinary Tumors Updates From the 5th Edition of the World Health Organization Blue Book Series. Archives of Pathology and Laboratory Medicine 148(8):952-964, 2024. e-Pub 2024. PMID: 38031818.
- Guo, CC, Lee, S, Lee, JG, Chen, H, Zaleski, M, Choi, W, McConkey, DJ, Wei, P, Czerniak, BA. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nature Reviews Urology 21(7):391-405, 2024. e-Pub 2024. PMID: 38321289.
- Zhao, J, Guo, CC, Rao, P. Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract. Advances in anatomic pathology 31(2):80-87, 2024. e-Pub 2024. PMID: 38009077.
- Guo, CC, Czerniak, BA. Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors. Journal of Clinical and Translational Pathology 3(1):26-34, 2023. e-Pub 2023.
- Fan, J, Guan, Y, Guo, CC, Wang, G. Testicular Germ Cell Tumors with Somatic-type Malignancy. Journal of Clinical and Translational Pathology 3(1):35-42, 2023. e-Pub 2023.
- Guo CC, Czerniak B. Reprint of: somatic-type malignancies in testicular germ cell tumors. Hum Pathol 133:102-114, 2023. e-Pub 2023. PMID: 36890027.
- Guo, CC, Shen, SS, Czerniak, BA. Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors. Bladder Cancer 9(1):1-14, 2023. e-Pub 2023. PMID: 38994481.
- Guo CC, Czerniak B. Molecular Taxonomy and Immune Checkpoint Therapy in Bladder Cancer. Surg Pathol Clin 15(4):681-694, 2022. e-Pub 2022. PMID: 36344183.
- Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of Bladder Cancer Pathology Assessment in Planning Clinical Trials. Urol Oncol 39(10):713-719, 2021. e-Pub 2021. PMID: 29395955.
Professional Educational Materials
- Harik LR, Paner GP Al-Ahmadie HA, Allan RW, Amin MB, Bilen MA, Bochner BH, Guo CC, Lopez-Beltran A, McKenney, JK, Sangoi AR, Sirintrapun SJ, Wadia R, Wobker SE, Zhou, M. Protocol for the Examination of Cystectomy Specimens From Patients With Carcinoma of the Urinary Bladder. College of American Pathologists, 2023.
- Harik LR, Paner GP Al-Ahmadie HA, Allan RW, Amin MB, Bilen MA, Bochner BH, Guo CC, Lopez-Beltran A, McKenney, JK, Sangoi AR, Sirintrapun SJ, Wadia R, Wobker SE, Zhou, M. Protocol for the Examination of Biopsy and Transurethral Resection of Bladder Tumor (TURBT) Specimens From Patients With Carcinoma of the Urinary Bladder. College of American Pathologists, 2023.
Other Articles
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA Erratum. iScience 25(7), 2022. PMID: 35811851.
Abstracts
- Clemente LC, Igel D, Pretzsch S, Matin S, Guo C. Expression of NECTIN4 and TROP2 in Resected Upper Tract Urothelial Carcinoma with and without Preoperative Chemotherapy. USCAP 105(3), 2026.
- Moosvi A, Yang R, Guo C, Zhao J. Clinicopathologic and Molecular Study of 15 Cases of Urothelial Carcinoma with Gene Fusions. USCAP 106(3), 2026.
- Zhao J, Yao J, Hosseini H, Baraban E, Lin R, Guo C, Huo L, Lu W, Khan K, Soto LS, Ding Q. FOXA1 is a Highly Sensitive Diagnostic Marker for Prostate Cancer Including Small Cell Carcinoma of Prostate. USCAP 115th Annual Meeting 106(3), 2026.
- Clemente LC, Zhang J, Parra E, Tamegnon A, Ibarguen H, Khan K, Pandurengan R, Zhang S, Kumar G, Haymaker C, Guo C, Wistuba I, Matin S. A Suppressive Tumor Microenvironment Is Associated with Higher Cancer Stage and Worse Outcome in Treatment-Naive Upper Tract Urothelial Carcinoma. Laboratory Investigation 104(S3):S912-S914, 2024. e-Pub 2024.
- Zheng L, Guo C, Tabet G, Rizvi Y, Raso MG, Liu J, Ding Q, Baraban E, Zhao J. Differential Expression of SOX17 in Clear Cell Adenocarcinoma of the Genitourinary and Gynecologic Tracts. Laboratory Investigation 104(S3):S891-2, 2024. e-Pub 2024.
- Zhang Q, Zheng L, Chen H, Roy-Chowdhuri S, Hansel D, Czerniak B, Guo CC. Mutational Profile of Small Cell Carcinoma of the Urinary Bladder. Laboratory Investigation 104(S3):S1088-S1089, 2024. e-Pub 2024.
- Tabet G, Zheng L, Hosseini H, Czerniak B, Guo CC. Testicular Epithelioid Trophoblastic Tumor – A Report of Five Cases. Laboratory Investigation 104(S3):S1060, 2024. e-Pub 2024.
- Shen Y, Zheng L, Zhao J, Wang Y, Wei P, Chen H, Roy-Chowdhuri S, Hansel D, Czerniak B, Guo CC. Molecular Profile of Micropapillary Urothelial Carcinoma of the Urinary Bladder: An Analysis of 99 Cases by Next Generation Sequencing. Laboratory Investigation 104(S3):S1054-S1055, 2024. e-Pub 2024.
- Hosseini H, Kokabee M, Czerniak B, Guo CC. Choriocarcinoma of the Testis: A Clinicopathological Study of 123 Cases. Laboratory Investigation 104(S3):S963-S964, 2024. e-Pub 2024.
- Czerniak B, Lee S, Jaksik R, Kus P, Wang Z, Lee JG, Navai N, Dinney C, McConkey D, Guo CC, Wang W, Wei P, Kimmel M. Dysregulation of Mucosal Microenvironment Drives the Progression of Urothelial Field Effects to Invasive Bladder Cancer. Laboratory Investigation 104(S3):S925, 2024. e-Pub 2024.
- Al-Attar M, Elzamly S, Zhang Q, Zheng L, Chen H, Roy-Chowdhuri S, Hansel D, Czerniak B, Guo C. Mutational Profile of Sarcomatoid Urothelial Carcinoma. Mod Pathol 104(3):S898-S899, 2024. e-Pub 2024.
- Rohra P, Shehabeldin A, Ebare K, Nair V, Zhao J, Czerniak B, Guo CC. Gene Mutations in Urothelial Carcinoma of the Upper Urinary Tract: An Analysis of 55 Cases by Next-Generation Sequencing. Laboratory Investigation 103(S3):S795, 2023. e-Pub 2023.
- Zheng L, Chen H, Zhao J, Czerniak B, Roy-Chowdhuri S, Guo CC. Mutational Landscape of Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: An Analysis of 51 cases by Next Generation Sequencing. Laboratory Investigation 103(S3):S839, 2023. e-Pub 2023.
- Zhao J, Czerniak B, Guo CC. Diagnostic Discordance of Upper Urinary Tract Urothelial Carcinoma between Biopsy and Nephroureterectomy Specimens: A Tertiary Cancer Center Experience. Laboratory Investigation 103(S3):S838, 2023. e-Pub 2023.
- Czerniak B, Lee S, Jung S, Kus P, Jaksik R, Lee JG, Chen H, Navai N, Guo CC, Wei P, Kimmel M. Modeling of Bladder Cancer Evolution from Whole-Organ Mutational and Proteomic Profiles. Laboratory Investigation 103(S3):S704, 2023. e-Pub 2023.
- Hotchandani N, Czerniak B, Guo CC. Clear Cell Adenocarcinoma of the Genitourinary Tract: A Clinicopathologic Study of 31 Cases. Modern Pathology 35(S2):599, 2022. e-Pub 2022.
- Shehabeldin A, Guo CC, Ebare K, Czerniak B, Hensley P. Gene Mutations in Urothelial Carcinoma of the Upper Urinary Tract. Modern Pathology 35(S2), 2022. e-Pub 2022.
- Zaleski M, Chen H, Czerniak B, Guo CC. Next-Generation Sequencing Analyses of Gene Mutations in Urachal Carcinoma. Modern Pathology 34(S2):530, 2021. e-Pub 2021.
- Zaleski M, Wang Z, Bondaruk J, Cogdell D, Lee S, Kimmel M, Wei P, Guo CC, Czerniak B. Immune Landscape of Bladder Cancer and Its Aggressive Highly Lethal Variants. Modern Pathology 34(S2):635, 2021. e-Pub 2021.
- Guo CC, Majewski T, Czerniak B. Genome-Wide Characterization of Sarcomatoid Bladder Cancer. Mod Pathol 32(S2):61, 2019. e-Pub 2019.
- Hwang MJ, Czerniak B, Guo CC. Clinicopathologic Analysis of Bladder Cancer Involving Muscularis Mucosae or Smooth Muscle of an Indeterminate Type on Transurethral Resection Specimens. Mod Pathol 32(S2):71, 2019. e-Pub 2019.
- Guo CC, Majewski T, Dinney C, Czerniak B. Useful Immunohistochemical Markers in the Molecular Classification of Bladder Cancer. Mod Pathol 32(S2):60-61, 2019. e-Pub 2019.
- Majewski T, Bondaruk J, Yao H, Lee S, Lee J, Zhang L, Guo CC, Dinney C, McConkey D, Baggerly K, Czerniak B. Genomic Profile of Field Effects and Their Progression to Clinically Evident Bladder Cancer. Mod Pathol 31(S2):363, 2018. e-Pub 2018.
- Guo CC, Majewski T, Zhang L, Bondaruk J, Kamat A, Dinney C, McConkey D, Czerniak B. Progression to Sarcomatoid Bladder Cancer is Associated with Dysregulation of Chromatin Remodeling and Cell Cycle Circuits. Mod Pathol 31(S2):346, 2018. e-Pub 2018.
- Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Molecular Characterization of Luminal and Basal Subtypes of Bladder Cancer. Mod Pathol 30(S2):219A, 2017. e-Pub 2017.
- Wang G, Xiao L, Zhang M, Czerniak B, Guo CC. Small Cell Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of 81 Cases. Mod Pathol 30(S2):266A, 2017. e-Pub 2017.
- Hruska CJ, Czerniak B, Guo CC. Paraganglioma of the Urinary Bladder: A Pathologic and Clinical Study of 26 Cases. Mod Pathol 30(S2):231A, 2017. e-Pub 2017.
- Dadhania V, Guo CC, Zhang M, Majewski T, Zhang L, Bondaruk J, Zhang S, Choi W, McConkey D, Dinney C, Baggerly K, Czerniak B. Molecular Subtypes of Bladder Cancer and Their Signature Markers in Multi-Institutional Cohorts. Mod Pathol 29(S2):224A, 2016. e-Pub 2016.
- Rao P, Naovarat B, Guo CC, Sircar K, Zhang M, Khalil F, Hernandez M, Tamboli P, Pettaway CA, Spiess PE, Dhillon J. Inter-Observer Variability among Urologic Pathologists in the Grading of Penile Squamous Cell Carcinoma. Mod Pathol 29(S2):257A, 2016. e-Pub 2016.
- Guo CC, Dadhania V, Zhang L, Bondaruk J, Majewski T, Sykulski M, Wronowska W, Gambin A, Kamat A, Dinney C, Choi W, McConkey D, Weinstein J, Czerniak B. Molecular Characterization of Clinically Aggressive Micropapillary Bladder Cancer. Mod Pathol 29(S2):235A, 2016. e-Pub 2016.
- Gilani S, Czerniak BA, Guo CC. Urothelial Carcinoma of the Upper Urinary Tract: A Clinicopathologic Study of 100 Cases. Mod Pathol 29(S2):232A, 2016. e-Pub 2016.
- Guo CC, Majewske T, Dadhania V, Willis D, Sykulski M, Wronowska W, Kamat A, Choi W, McConkey D, Dinney C, Gamblin A, Czerniak B. Gene Expression Profile of Micropapillary Bladder Cancer. Mod Pathol 28(S2):225A, 2015. e-Pub 2015.
- Zhang M, Guo CC, Majewski T, Dadhania V, Skyulski M, Wronowska W, Choi W, McConkey D, Dinney C, Gambin A, Czerniak B. Immunohistochemical Profiles of Molecular Subtypes of Bladder Cancer. Mod Pathol 28(S2):270A, 2015. e-Pub 2015.
- Liang Y, Wani K, Wang Y, Czerniak B, Guo CC. Distinct Expression of MicroRNAs in Micropapillary Variant of Urothelial Carcinoma. Mod Pathol 28(S2):239A, 2015. e-Pub 2015.
- Huang H, Xiao L, Zhang M, Czerniak B, Guo CC. Sarcomatoid Carcinoma of the Urinary Bladder: A Clinicopathological Analysis of 73 Cases. Mod Pathol 28(S2):229A, 2015. e-Pub 2015.
- Fox M, Xiao L, Czerniak B, Guo CC. Plasmacytoid Variant of Urothelial Carcinoma: A Clinocopathological Study of 49 Cases. Mod Pathol 28(S2):221A, 2015. e-Pub 2015.
- Li W, Liang Y, Deavers MT, Czerniak B, Guo CC. Uroplakin II is more sensitive than uroplakin III in urothelial carcinoma and its variants. Mod Pathol 27(S2):244A, 2014. e-Pub 2014.
- Liang Y, Heitzman J, Czerniak B, Guo CC. Differential Expression of GATA-3 in Urothelial Carcinoma Variants. Mod Pathol 27(S2):244A, 2014. e-Pub 2014.
- Heitzman J, Czerniak B, Guo CC. Using Cytokeratin Expression Pattern to Evaluate Differentiation in Urothelial Carcinoma of the Upper Urinary Tract. Mod Pathol 26(S2):217A, 2013. e-Pub 2013.
- Henderson SA, Heitzman JP, Czerniak B, Guo CC. Microsatellite Instability in Urothelial Carcinoma of the Upper Urinary Tract. Mod Pathol 26(S2):217A, 2013. e-Pub 2013.
- Murugan P, Tamboli P, Czerniak B, Guo CC. Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Mod Pathol 26(S2):237A, 2013. e-Pub 2013.
- Clemente L, Zhang J, Parra E, Tamegnon A, Ibarguen H, Khan K, Pandurengan R, Zhang S, Kumar G, Haymaker C, Guo C, Wistuba I, Matin S. A Suppressive Tumor Microenvironment Is Associated with Higher Cancer Stage and Worse Outcome in Treatment-Naive Upper Tract Urothelial Carcinoma. Mod Pathol 104(3):S912-S914, 2004. e-Pub 2004.
- Price DT, Dell Rocca G, Eckhart AD, Guo C, Ballo MS, Daaka Y, Schwinn DA, Luttrell LM. Increased activation of extracellular signal regulated kinase in human prostate cancer. AACR Proceeding, Special Meeting on Prostate Cancer Biology, 1998. e-Pub 1998.
- Mi W, Guo C, Zhao J, Hansel D, Czerniak B, Chen H. Molecular Profile of Upper Tract Urothelial Carcinoma: An Analysis of 110 Cases by Next-Generation Sequencing. USCAP 115th Annual Meeting 106(3).
Book Chapters
- Guo CC. 122. Molecular Genomics of Bladder Cancer. In: Uropathology. 2nd. Elsevier, 275-278, 2022.
- Guo CC. 158. Clear Cell Papillary Renal Cell Carcinoma. In: Uropathology. 2nd. Elsevier, 358-359, 2022.
- Guo CC. 216. Postpubertal-Type Teratoma. In: Uropathology. 2nd. Elsevier, 483-484, 2022.
- Guo CC. 215. Postpubertal-Type Yolk Sac Tumor. In: Uropathology. 2nd. Elsevier, 480-482, 2022.
- Guo CC. 214. Embryonal Carcinoma. In: Uropathology. 2nd. Elsevier, 477-479, 2022.
- Guo CC. 213. Seminoma. In: Uropathology. 2nd. Elsevier, 473-476, 2022.
- Guo CC. 202. Postpubertal Gonadotrophin Deficiency. In: Uropathology. 2nd. Elsevier, 453, 2022.
- Guo CC. 189. Testis - Anatomy and Histology. In: Uropathology. 2nd. Elsevier, 428-429, 2022.
- Guo CC. 171. Wilms Tumor. In: Uropathology. 2nd. Elsevier, 389--391, 2022.
- Guo CC. 27. Intraductal Carcinoma of the Prostate. In: Uropathology. 2nd. Elsevier, 56-58, 2022.
- Guo CC. 46. Urothelial Carcinoma of the Prostate. In: Uropathology. 2nd. Elsevier, 105-107, 2022.
- Guo CC. 70. Polypoid and Papillary Cystitis. In: Uropathology. 2nd. Elsevier, 166-167, 2022.
- Guo CC. 98. Urothelial Carcinoma with Squamous Differentiation. In: Uropathology. 2nd. Elsevier, 225, 2022.
- Guo CC. 132. Simple Cortical Cyst in the Kidney. In: Uropathology. 2nd. Elsevier, 299, 2022.
- Guo CC, Aron M, Lopez-Beltran A, Paner G, Reis H. Bladder Adenocarcinoma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs. 5. WHO Press, 173-176, 2022.
- Guo CC. 293. Mixed Squamous Cell Carcinoma of the Penis. In: Uropathology. 2nd. Elsevier, 629-630, 2022.
- Guo CC. 269. Primary Urethral Carcinoma. In: Uropathology. 2nd. Elsevier, 586-587, 2022.
- Guo CC. 260. Epithelial Tumors of the Rete Testis. In: Uropathology. 2nd. Elsevier, 569-570, 2022.
- Guo CC. 248. Adenomatoid Tumor. In: Uropathology. 2nd. Elsevier, 549-550, 2022.
- Guo CC. 240. Testicular Cancer Staging. In: Uropathology. 2nd. Elsevier, 533, 2022.
- Guo CC. 223. Prepubertal-Type Teratoma - Testicular Carcinoid Tumor. In: Uropathology. 2nd. Elsevier, 496-497, 2022.
- Guo CC. 218. Teratoma with Somatic-Type Malignancies. In: Uropathology. 2nd. Elsevier, 487-488, 2022.
- Guo, CC, Ro, JY, Czerniak, BA. Invasive urothelial carcinoma with molecular types, 45-61, 2021.
- Zhou, HJ, Guo, CC, Ro, JY. Conclusion and remarks, 249-252, 2021.
- Zhou, HJ, Guo, CC, Ro, JY. Papillary and inverted tumors, 35-44, 2021.
- Zhou, HJ, Guo, CC, Ro, JY. Introduction to urinary bladder pathology, 1-5, 2021.
- Guo CC, Ro JY, Czerniak B. Invasive urothelial carcinoma with molecular types. In: Bladder Cancer: Recent Advances in Surgical and Molecular Pathology. 1. Springer, 45-61, 2021.
- Zynger DL, Guo CC. Testis and Paratesticular Lesions. In: Practical Genitourinary Pathology: Frequently Asked Questions. First. Springer, 187-246, 2021.
- Zhou HJ, Guo CC, Ro JY. Papillary and Inverted Tumors. In: Urinary Bladder Pathology. 1. Springer, 35-44, 2021.
- Divatia MK, Guo CC, Rehman A, Ro JY. Major Subtypes of Renal Cell Carcinoma. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. First. Springer, 77-114, 2020.
- Guo CC, Zhang M, Sircar K. Tumors of the Renal Pelvis. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. First. Springer, 261-281, 2020.
- Zhang M, Guo CC. Neuroendocrine Kidney Tumors. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. First. Springer, 193-205, 2020.
- Ulbright T, Amin MB, Balzer B, Berney DM, Epstein JI, Guo CC, Idrees MT, Looijenga LHJ Paner G, Rajpert-De Meyts E, Skakkebaek NE, Tickoo, SK, Yilmaz A, Oosterhuis JW. Germ Cell Tumors. In: The WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th. International Agency for Research on Cancer (IARC), 189-226, 2016.
- Guo CC. Adenocarcinoma. In: Advances in Surgical Pathology: Bladder Cancer. 1st. Wolters Kluwer, 136-148, 2016.
- Guo CC. Neoplasms of the Testis. In: Genitourinary Pathology. 2nd. Elsevier Science, 600-687, 2015.
- Guo CC, Smith AK, Pavlovich CP. Familial Forms of Renal Cell Carcinoma and Associated Syndromes. In: The Kidney: A Comprehensive Guide to Pathologic Diagnosis and Management. 1. Springer, 81-96, 2015.
- Guo CC. Mixed carcinomas. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 499, 2012.
- Guo CC. Primary urethral carcinoma. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 473, 2012.
- Guo CC. Neoplasms of the rete testis. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 430-431, 2012.
- Guo CC. Adenomatoid tumor. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 442-443, 2012.
- Guo CC. Testicular cancer stage. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 432, 2012.
- Guo CC. Testicular carcinoid tumor. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 403-404, 2012.
- Guo CC. Teratoma with secondary malignant components. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 401-402, 2012.
- Guo CC. Teratoma. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 397-398, 2012.
- Guo CC. Yolk sac tumor. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 394-396, 2012.
- Guo CC. Embryonal carcinoma. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 391-393, 2012.
- Guo CC. Seminoma. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 386-389, 2012.
- Guo CC. Postpubertal gonadotropin deficiency. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 368, 2012.
- Guo CC. The testitis: normal anatomy and histology. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 350-351, 2012.
- Guo CC. Wilms tumor. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 306-308, 2012.
- Guo CC. Clear cell papillary renal cell carcinoma. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 298-299, 2012.
- Guo CC. Simple renal cortical cyst. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 244, 2012.
- Guo CC. Urothelial carcinoma with squamous differentiation. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 190, 2012.
- Guo CC. Polyploid and papillary cystitis. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 144-145, 2012.
- Guo CC. Intraductal carcinoma of the prostate. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 55-56, 2012.
- Guo CC. Urothelial carcinoma of the prostate. In: High Yield Pathology: Genitourinary Pathology. First. Elsevier, 92-93, 2012.
- Guo CC, Moore C. Inflammatory and Infectious diseases. In: The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management. First. Springer, 63-79, 2012.
Books (edited and written)
- Zhou HJ, Guo CC, Ro JY. Urinary Bladder Pathology. Ed(s) First. Springer, 2021.
- Divatia MK, Ozcan A, Guo CC, Ro JY. Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. Ed(s) First. Springer, 2020.
Patents
- Gao JJ, Logothetis C, Chen J, Alhalabi O, Wang L, Titus M, Czerniak B, Guo CC, Wang WL, Zhang M, Campbell M, Shah A. Combination therapy with anti-folate agents and MTAP receptor antagonists for MTAP-deficient tumors. Patent Number: USA MDA 17-129.
Patient Reviews
CV information above last modified September 18, 2026